UNASSIGNED: @entity68 stores assuring optimal efficacy/safety for erythropoiesis are unknown in the dialysis population. Using multicenter trial data, we related safety profiles, erythropoiesis-stimulating agent (ESA), and intravenous @entity68 dosing to achieved @entity68 stores in 441 subjects randomized 2  :  1 to @entity17391 or active control as their @entity4613 binder over 52  weeks. Intravenous @entity68 was given at each site's discretion if ferritin <=   1,000  ng/mL and @entity69 saturation <=   30%. Multivariable time-dependent Cox regression jointly related the primary safety outcome (composite of cardiac, @entity281 , gastrointestinal, and hepatobiliary serious adverse events) to moving averages of ferritin and @entity69 saturation over the preceding 90  days with covariate adjustment. Multivariable generalized estimating equations related elevated ESA and intravenous @entity68 doses to trailing 90-day averages of ferritin and @entity69 saturation with covariate adjustment. The adjusted hazard ratio for the safety composite per 10% increase in @entity69 saturation was 0.84 (95% confidence interval 0.68  -  1.02, p  =  0.08) and 1.09 (0.86  -  1.35, p  =  0.48) per 400  ng/mL increase in ferritin. The adjusted hazard ratio for the safety composite was 0.50 (0.29  -  0.88, p  =  0.016) for the highest @entity69 saturation tertile vs. the lowest. Adjusted odds ratios for higher intravenous @entity68 dose were lower in the highest (0.23 [0.16  -  0.35], p  <  0.001) and middle @entity69 saturation tertile (0.42 [0.31  -  0.57], p  <  0.001) vs. lowest. Incidence of elevated ESA dose was lower in the highest @entity69 saturation tertile (p  =  0.01). Ferritin did not predict clinical events or ESA dose. @entity69 saturation may be a better marker than serum ferritin to judge optimal @entity68 stores in dialysis @entity1 . @entity69 saturations >  34% are safe and provide maximal efficacy.

The safety of achieved @entity68 stores and their effect on IV @entity68 and ESA use: post-hoc results from a randomized trial of XXXX as a @entity4613 binder in dialysis   .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity17391 :: ('MESH:C025314', 'Chemical') :: ['ferric citrate'] @entity4613 :: ('D010710', 'Chemical') :: ['phosphate'] @entity69 :: ('7018', 'Gene') :: ['Transferrin', 'transferrin'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity68 :: ('MESH:D007501', 'Chemical') :: ['iron', 'Iron']
@entity17391 :: (MESH:C025314,Chemical) :: ['ferric citrate']
